MicrobioticaCambridge-based Microbiotica’s ulcerative colitis (UC) candidate met its primary and secondary phase 1b study objectives on safety, efficacy signals and bacterial engraftment. The company has reported positive results from a small, placebo-controlled study of its oral precision microbiome therapy MB310 in patients with mild-to-moderate ulcerative colitis, adding a rare positive clinical signal in a disease area where microbiome approaches have so far struggled to gain traction.
Tag Archive for: clinical data
Leyden Labs has released new early-stage data on its intranasal antibody program for influenza prevention, adding phase 1 human safety results to previously disclosed animal studies.
MAES-AREA-EnglosLille-based Genfit SA has discontinued Phase II development of its lead drug candidate VS-01, a liposomal ammonia scavenger designed to prevent organ failure in acute chronic liver failure (ACLF). The company will reprioritise its (preclinical) pipeline, including VS-01, which will be further developed in the area of urea cycle disorder (UCD).
Sphene CapitalDespite the recent stock market rally and declining volatility, IPOs are rather rare in many industrialised countries –not least for seasonal reasons. The main reason for this, however, is the aggressive monetary policy of the central banks, with more than ten interest rate hikes in both Europe and the US.
Precision medicine tailors therapeutics to individual patients’ diseases, and is seen as the future of clinical practice. With significant time and financial investments being made in developing therapeutics, the ultimate success of patient-data driven precision therapies hinges on three main factors: the quality of the tissue samples, the associated molecular data, and the analysis used in their development.